Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term PROGRESSION. Found 12 abstracts

DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, ACOSOG Intergrp Adjuvant GIST Stud. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009 Mar;373(9669):1097-104.   PMCID: PMC2915459
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology. 2008 Feb;26(4):626-32.
Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008 Mar;452(7184):187-U36.
Horiguchi A, Chen DY, Goodman OB, Zheng R, Shen R, Guan H, Hersh LB, Nanus DM. Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis. Prostate Cancer and Prostatic Diseases. 2008 Mar;11(1):79-87.
Balogh GA, Heulings R, Mailo D, Wang R, Li YS, Hardy R, Russo J. Methodological approach to study the genomic profile of the human breast. International Journal of Oncology. 2007 Aug;31(2):253-60.
Beissel B, Silva I, Pesquero JB, Russo J, Schor N, Bellini MH. S-phase reduction in T47D human breast cancer epithelial cells induced by an S100P antisense-retroviral construct. Oncology reports. 2007 Mar;17(3):611-5.
Cai KQ, Yang WL, Capo-Chichi CD, Vanderveer L, Wu H, Godwin AK, Xu XX. Prominent expression of metalloproteinases in early stages of ovarian turnorigenesis. Molecular Carcinogenesis. 2007 Feb;46(2):130-43.
Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology. 2007 Jun;60(1):81-9.
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mobuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology & Therapy. 2007 Nov;6(11):1717-25.
Jin TC, Guo F, Serebriiskii IG, Howard A, Zhang YZ. A 1.55 a resolution X-ray crystal structure of HEF2/ERH and insights into its transcriptional and cell-cycle interaction networks. Proteins-Structure Function and Bioinformatics. 2007 Aug;68(2):427-37.
Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, Dargemont C, Garcia de Herreros A, Bellacosa A, Larue L. Activation of NF-kappa B by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007 Nov;26(53):7445-56.
Klein WM, Wu BP, Zhao SP, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Modern Pathology. 2007 Jan;20(1):102-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term PROGRESSION

PROGRESSION SURVIVAL IN-VIVO EXPRESSION GENE-EXPRESSION PROFILES INHIBITOR CELLS BINDING MUTATIONS CANCER angiogenesis PURIFICATION PROGNOSTIC-FACTORS ovarian cancer ACUTE MYELOID-LEUKEMIA APOPTOSIS NSCLC RUDIMENTARY HOMOLOG migration slug TUMOR DISABLED-2 SAFETY tyrosine kinase inhibitor BEVACIZUMAB MRI TUMOR-SUPPRESSOR GENE TYROSINE KINASE INHIBITOR BINDING PROTEIN SIGNAL-TRANSDUCTION DYSREGULATED EXPRESSION CELL-MIGRATION epithelium PROPHYLACTIC OOPHORECTOMIES ST1571 lentivirus LASER CAPTURE MICRODISSECTION IN-SITU AGENT EXTRACELLULAR-MATRIX OLIGONUCLEOTIDE MICROARRAY ANALYSIS chemotherapy LENTIVIRAL VECTORS ANGIOGENESIS TYROSINE KINASE AMERICAN JOINT COMMITTEE MODEL BRAIN HUMAN PLACENTA BREAST-CANCER SARCOMA-GROUP YEAST SACCHAROMYCES-CEREVISIAE FIBROBLAST GROWTH FACTOR-2 FCP1 PHOSPHATASE GENE EFFICACY TRANSCRIPTION FACTOR SNAIL RESISTANCE S100P E-cadherin CELL INVASION stem cell melanoma-CD133-CD166-nestin E-CADHERIN EXPRESSION CHROMATIN Zeb CARCINOMA TRANSGENIC MICE CANCER METASTASIS E-CADHERIN TUMORIGENICITY RNA-POLYMERASE-II IDENTIFICATION EPITHELIAL-MESENCHYMAL TRANSITIONS paclitaxel membrane NESTIN EXPRESSION PHASE-III TUMOR-GROWTH antisense phase I neutral PROSTATE-CANCER ARCHITECTURE ENDOTHELIAL GROWTH-FACTOR REPRESSES ARRAYS HYDROXYLASE-STIMULATING PROTEIN calcium-binding protein preclinical basic fibroblast growth factor GENE-THERAPY cell cycle transcription factor-HNF1-RNAPII-SPT5-FCP1-VHL SMAD-INTERACTING PROTEIN-1 CANCER-RISK carboplatin breast laser capture microdissection-microarray-PCR amplification-linear amplification KIT OVULATION DIMERIZATION SKIN transgenic mouse model DOSE IMATINIB model FAMILY PROMOTER metastasis MATRIX METALLOPROTEINASES MMPs C-KIT TUMORS SURFACE EPITHELIAL-CELLS pharmacokinetics RNA PROTEIN EXPRESSION basement T47D MRI micro-imaging preneoplastic changes endopeptidase GEFITINIB HUMAN ENHANCER POLYMERASE CHAIN-REACTION VEGFR-2
Last updated on Wednesday, February 05, 2020